Incyte的鲁索替尼乳膏在中期皮炎研究中取得成功
2020-04-07 12:24:49来源：
一项评估Incyte（NASDAQ：INCY）ruxolitinib乳膏治疗特应性皮炎（AD）患者的2b期临床试验达到了主要终点。每天接受两次局部治疗的患者在第4周的EASI得分（湿疹面积和严重程度指数）得分提高了71.6％，而媒介物（安慰剂）的得分为15.5％（p<0.001).Ruxolitinib cream also demonstrated non-inferiority (no worse than) to the active control, triamcinolone 0.1% cream (a mid-potency topical corticosteroid) at week 4.On the safety front, ruxolitinib cream was well-tolerated with no significant treatment-related adverse events.Development is ongoing.Now read: Avita Medical: An Undervalued Wound Care Company With 50% Upside Potential And Real TechnologyOriginal articleiv>
郑重声明：本文版权归原作者所有，转载文章仅为传播更多信息之目的，如有侵权行为，请第一时间联系我们修改或删除，多谢。
